[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369615-105":59,"doc-detail-369615-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","challenges-and-resistance-mechanisms-to-egfr-targeted-therapies-in-head-and-neck-cancers-and-breast-cancer-review","Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer - Review","","Epidermal Growth Factor Receptor (EGFR) targeted therapies show inconsistent clinical performance in breast and head and neck cancers, even though EGFR is frequently overexpressed. Primary resistance is widespread, while secondary resistance often develops through increased activity of other receptor tyrosine kinases (RTKs) and enhanced downstream signaling. Non-RTK pathways further contribute to failure, including AXL, MET, and RON RTK families and additional signaling changes that sustain tumor progression and survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/challenges-and-resistance-mechanisms-to-egfr-targeted-therapies-in-head-and-neck-cancers-and-breast-cancer-review/369615/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/challenges-and-resistance-mechanisms-to-egfr-targeted-therapies-in-head-and-neck-cancers-and-breast-cancer-review/369615.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do EGFR targeted therapies have variable results in breast and head and neck cancers?","Question",{"text":113,"@type":114},"EGFR targeted therapies yield variable trial outcomes despite EGFR overexpression. Primary resistance is common and secondary resistance can arise from other RTKs and strengthened downstream signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What RTK-related pathways contribute to resistance to anti-EGFR therapies?",{"text":118,"@type":114},"Resistance involves overexpression and signaling from other receptor tyrosine kinases, with emphasis on AXL, MET, and RON families. These RTKs can drive tumor progression and maintain survival signaling even when EGFR is inhibited.",{"name":120,"@type":111,"acceptedAnswer":121},"What non-RTK-driven mechanisms are discussed as resistance contributors?",{"text":122,"@type":114},"Non-RTK mechanisms include EGFR activation via EGF-related ligands, nuclear localization of EGFR, and overexpression of resistance-conferring proteins in breast cancer. In head and neck cancer, TLR4-MyD88 signaling activation, PTEN loss, PI3K activating mutations, and STAT3 involvement are highlighted.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369615,1790738402,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www.oncotarget.com](www.oncotarget.com) Oncotarget, 2025, Vol. 16, pp: 508-530  \nReview  \nChallenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms  \nShreya Shyamsunder 1,*, Zhixin Lu2,*, Vinita Takiar 1,3 and Susan E . Waltz2,3 1 Department of Radiation Oncology, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA 2 Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA 3 Research Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220, USA  \n*These authors contributed equally to this work  \nCorrespondence to: Susan E. Waltz, email: [susan.waltz@uc.edu](susan.waltz@uc.edu)  \nVinita Takiar, email: [takiarva@ucmail.uc.edu](takiarva@ucmail.uc.edu)[ ](takiarva@ucmail.uc.edu)Keywords: EGFR; RTKs; breast cancer; head and neck cancer; resistance mechanisms  \nReceived: January 23, 2025 Accepted: June 07, 2025 Published: June 25, 2025  \nCopyright: © 2025 Shyamsunder et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4 .0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nEpidermal Growth Factor Receptor (EGFR) targeted therapies have yielded variable results in clinical trials for breast and head and neck cancers, despite EGFR overexpression in these malignancies. Primary resistance to these therapies is common, with secondary resistance often arising due to the overexpression of other receptor tyrosine kinases (RTKs) and increased downstream signaling from these  \nRTKs. Additionally, non-RTK-driven mechanisms also contribute to anti-EGFR therapy resistance. This review highlights the role of AXL, MET, and RON families of RTKs in tumor progression and resistance to anti-EGFR therapies, focusing on breast and head and neck cancers. In breast cancer, the review discusses the intricate relationship between EGFR expression and therapeutic outcomes, emphasizing the challenges and potential strategies for enhancing EGFR-targeted treatments. It details how EGFR inhibition affects tumor progression and survival in head and neck cancer, noting that small molecule inhibitors and monoclonal antibodies, such as cetuximab, can lead to trans-activation of other RTKs. The review further explores non-RTK-driven resistance mechanisms in breast cancer, including EGFR activation through EGF-related ligands, nuclear localization of EGFR, and the overexpression of resistance-conferring proteins. In head and neck cancer, resistance is also mediated by TLR4-MyD88 signaling activation, loss of tumor suppressor genes like PTEN, activating mutations in PI3K, and involvement of STAT3. By synthesizing current insights on both RTK and non-RTK mediated resistance against anti-EGFR therapies, this review aims to guide future research and improve therapeutic strategies for these cancers.  \nINTRODUCTION  \nReceptor tyrosine kinases (RTKs) constitute a family of highly conserved proteins that are overexpressed in multiple cancers, making them prime candidates for the development of targeted therapies. RTKs are characterized by structural features, including an extracellular domain responsible for ligand binding, a transmembrane domain, and an intracellular domain with kinase activity. In their  \ninactivated state, RTKs may exist as monomers or in a closed conformational state, but upon ligand binding, they can dimerize, leading to the phosphorylation of tyrosine residues within the intracellular domain (i.e., EGFR family members) [1] . However, some RTKs dimerize even in the absence of ligands (i.e., the insulin receptor) [2, 3] with RTK dimers formed in the absence of ligands becoming further stabilized with ligand binding [3] . Dimerization is then followed by phosphorylation  \nevents which subsequently activate downstream si","cbCaiv2EFoao7y1M","https://ap.wps.com/l/cbCaiv2EFoao7y1M","pdf",3384175,23,"English","# ABSTRACT\n# INTRODUCTION","[{\"question\":\"Why do EGFR targeted therapies have variable results in breast and head and neck cancers?\",\"answer\":\"EGFR targeted therapies yield variable trial outcomes despite EGFR overexpression. Primary resistance is common and secondary resistance can arise from other RTKs and strengthened downstream signaling.\"},{\"question\":\"What RTK-related pathways contribute to resistance to anti-EGFR therapies?\",\"answer\":\"Resistance involves overexpression and signaling from other receptor tyrosine kinases, with emphasis on AXL, MET, and RON families. These RTKs can drive tumor progression and maintain survival signaling even when EGFR is inhibited.\"},{\"question\":\"What non-RTK-driven mechanisms are discussed as resistance contributors?\",\"answer\":\"Non-RTK mechanisms include EGFR activation via EGF-related ligands, nuclear localization of EGFR, and overexpression of resistance-conferring proteins in breast cancer. In head and neck cancer, TLR4-MyD88 signaling activation, PTEN loss, PI3K activating mutations, and STAT3 involvement are highlighted.\"}]","Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer - Review | PDF",1790183684,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/555ae4cfee06f0c7feda50bf0a33a672.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c42e6b7b5e5eb416fb0da393cbe215c.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8827aed3d9c96ad1b2310645cc547ce6.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c9fb8761afcc4adecec381746dcc65b.webp",980,1268]